By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Provectus Biopharmaceuticals Inc. 

7327 Oak Ridge Highway Suite B

Knoxville  Tennessee  37931  U.S.A.
Phone: 866-594-5999 Fax:


Company News
Provectus Biopharmaceuticals Inc. Will Hold Its 2014 Year-End Quarterly Business Update Conference Call At 4 PM Eastern, Thursday, March 12, 2015 2/24/2015 10:47:46 AM
Provectus Biopharmaceuticals Inc. Will Present at 8th Annual European Life Science CEO Forum & Exhibition 2/18/2015 1:49:39 PM
Provectus Biopharmaceuticals Inc. Release: Late Melanoma Patients Will Need Several Lines of Therapy, Intralesional Treatment Promising Says New Paper 2/12/2015 12:21:20 PM
Provectus Biopharmaceuticals Inc. Will Present At 17th Annual BIO CEO And Investor Conference Tuesday, February 10, 2015 2/10/2015 12:07:35 PM
Provectus Biopharmaceuticals Inc. Met With FDA On Operational Aspects Of PV-10 Phase 3 Melanoma Study 2/9/2015 10:31:01 AM
Provectus Biopharmaceuticals Inc.’s PV-10 Featured In Article By Sanjiv Agarwala In Current Opinion In Oncology 2/6/2015 10:50:18 AM
Provectus Biopharmaceuticals Inc. Begins Recruitment For Phase 2 Mechanism Of Action Clinical Trial Of PH-10 For Psoriasis 1/29/2015 10:44:57 AM
Provectus Biopharmaceuticals Inc.’ Novel Synthesis Patent Application Allowed By Chinese Patent Office 1/26/2015 10:02:53 AM
Provectus Biopharmaceuticals Inc.’ Protocol For Phase 2 Study Of Mechanism Of Action Of PH-10 On Immunologic Makers Of Psoriasis Now Available Online 12/23/2014 10:36:24 AM
Provectus Biopharmaceuticals Inc. To Meet With FDA On Operational Aspects Of PV-10 Phase 3 Melanoma Study With Aim To Maximize Speed Of Enrollment 12/22/2014 11:45:42 AM